Hypothesis

Engineered hybrid exosomes that display a senescent‑cell‑specific ligand (e.g., anti‑uPAR scFv) and carry a dual RNA payload—siRNA against p16 and a short hairpin RNA that transiently inhibits mTOR—will preferentially deliver their cargo to senescent cells, causing rapid p16 knock‑down and a pulsatile mTOR suppression that together trigger SASP attenuation and tissue rejuvenation.

Mechanistic Rationale

1. Exosome membranes naturally present tetraspanins and adhesion proteins that can be genetically fused to targeting moieties without losing vesicle integrity [1].
2. Loading functional RNAs via RNA‑binding protein adapters (e.g., Pumilio‑HF) enables high‑efficiency encapsulation of both siRNA and shRNA molecules [4].
3. Senescent cells overexpress surface markers such as uPAR; directing exosomes to these markers increases local concentration and reduces off‑target uptake [3].
4. Simultaneous p16 silencing removes a key cell‑cycle arrest effector, while brief mTOR inhibition reduces SASP translation and promotes autophagy, a combination shown to synergize in clearing senescent phenotypes [2][5].
5. The hybrid design retains the lipid bilayer’s immune‑evading properties and adds the manufacturing scalability of liposomes, addressing the production bottlenecks highlighted in recent reviews [1].

Testable Predictions

• In vitro, hybrid exosomes will reduce p16 protein levels by >50 % in irradiated human fibroblasts after 24 h, whereas non‑targeted exosomes or liposomes loaded with the same RNAs will show <20 % reduction.
• Blocking the uPAR‑binding ligand with excess soluble uPAR will abolish the preferential uptake and the downstream p16 knock‑down, falsifying the targeting claim.
• In aged mice (24 months), intravenous injection of hybrid exosomes twice weekly for four weeks will decrease SA‑β‑gal positive cells in liver and kidney by at least 30 % and lower circulating IL‑6 levels, while control groups receiving untreated exosomes will not reach this threshold.
• Rapamycin co‑administration will not further improve outcomes, indicating that the mTOR‑modulating shRNA already provides the optimal pulsatile inhibition.

Falsifiability

• Hybrid exosomes fail to show superior cargo delivery to senescent cells compared with non‑targeted vesicles in quantitative fluorescence assays.
• p16 knock‑down does not correlate with reduced SASP markers despite efficient RNA delivery.
• Therapeutic benefits are absent in vivo despite confirmed cellular uptake and RNA activity.
• The observed effects are entirely dependent on continuous mTOR inhibition rather than the designed transient pulse, indicating the shRNA component is ineffective.